Welcome to the second Innovation Magazine from the UCLA Technology Development Group. In this issue we highlight UCLA TDG accomplishments in recent months! Our many projects are fully under way and we have established partnerships at multiple levels within the UC ecosystem, investors and with industry professionals. Featured in this issue of the magazine is storytelling and background on the TDG team, our recent deal making, what we do and how we’ve arrived at our success and growth.
In this episode, Kirsten Leute speaks with Amir Naiberg, Associate Vice Chancellor and CEO & President, UCLA Technology Development Corporation, about his experiences in technology transfer in Israel and the US.
Eighteen professors, researchers and clinicians at UCLA have been named recipients of awards from the 2017 UCLA Innovation Fund Biomedical Competition, which was established to quickly move technologies from idea to the marketplace and bridge the gap between academia and industry-investor interest to provide benefit to patients and the public.
Ragan Robertson, Tech Transfer and Information Systems Officer for the UCLA Technology Development Group, has been recognized by AUTM (Association of University Technology Managers) with the 2018 Bayh-Dole Award for his efforts to foster and promote intellectual property activities on behalf of the university and nonprofit community. CONGRATULATIONS, RAGAN!
Falcon Computing Solutions and the UCLA Center for Precision Medicine today announced a collaboration that will accelerate innovation and the adoption of cloud-based genomics sequencing solutions. Falcon is conducting initial product testing, benchmarking and optimization at UCLA based on the industry standard GATK best practices pipeline, and is receiving valuable feedback from the UCLA researchers and scientists that allow for product optimization. The joint activity builds upon an existing relationship between UCLA and Falcon – a UCLA spinout co-founded by Dr.
20 startups, 21 new staff members, and $41.8 million in ISR in the 2017 fiscal year. Learn more about what we've accomplished, and what we hope to do next in the TDG Newsletter, Vol.1.
The trial investigated the effects of eTNS on ADHD as the sole treatment, or "monotherapy." A total of 62 children were enrolled in the trial and used the eTNS therapy each night, at home, for four weeks. The trial's primary endpoint assessment, the ADHD-RS, showed that subjects randomized to active treatment had a statistically significant improvement in their ADHD symptoms compared with the sham group (p = 0.005). The CGI-I scale, a secondary endpoint, also demonstrated statistically significant improvements in ADHD symptoms among subjects randomized to the treatment group (p = 0.003).
Professor Aydogan Ozcan, UCLA’s Chancellor’s Professor of Electrical Engineering and Bioengineering and an associate director of the California NanoSystems Institute, and Thomas Lipkin, head of new ventures for the UCLA Technology Development Group, have been recognized by Biocom, the association representing the California life science community, with Life Science Catalyst Awards.
The odds of developing a blockbuster drug are slim. Thousands of compounds are screened, and only about one in 10 drugs that survive the initial stages to enter clinical trials eventually receives approval. The road from discovery to drug product can take more than a decade and cost more than $2 billion.
How can the drug discovery process be improved?
Bosley recently finalized the lung phantom’s first prototype, which he will take to partners at UCLA; next, he hopes to start printing lungs from actual patients’ CT scans and let oncologists test the simulator. The patent-pending technology, owned by UCF and UCLA and is licensed to SegAna, will cost in the $8,000 range, Bosley said. It can be used as a teaching tool, or for planning patients’ radiation treatment.